Business Description
F-star Therapeutics Inc
NAICS : 325412
SIC : 2834
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
Compare
Compare
Traded in other countries / regions
S4BA.Germany
•
FSTX.USA
Description
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.27 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.42 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 2.01 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.79 | |||||
9-Day RSI | 69.74 | |||||
14-Day RSI | 72.71 | |||||
6-1 Month Momentum % | 82.89 | |||||
12-1 Month Momentum % | -6.2 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.11 | |||||
Quick Ratio | 6.11 | |||||
Cash Ratio | 5.44 | |||||
Days Sales Outstanding | 49.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -150.97 | |||||
Net Margin % | -162.42 | |||||
ROE % | -41.31 | |||||
ROA % | -31.82 | |||||
ROIC % | -71.4 | |||||
ROC (Joel Greenblatt) % | -715.92 | |||||
ROCE % | -33.92 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.53 | |||||
PB Ratio | 1.59 | |||||
Price-to-Tangible-Book | 2.57 | |||||
EV-to-EBIT | -2.68 | |||||
EV-to-EBITDA | -2.82 | |||||
EV-to-Forward-EBITDA | -1.65 | |||||
EV-to-Revenue | 4.15 | |||||
EV-to-Forward-Revenue | 13.83 | |||||
EV-to-FCF | -3.5 | |||||
Price-to-Net-Current-Asset-Value | 2.78 | |||||
Price-to-Net-Cash | 3.34 | |||||
Earnings Yield (Greenblatt) % | -37.41 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:FSTX
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 20.801 | ||
EPS (TTM) ($) | -1.54 | ||
Beta | 0 | ||
Volatility % | 131.22 | ||
14-Day RSI | 72.71 | ||
14-Day ATR ($) | 0.177063 | ||
20-Day SMA ($) | 6.364 | ||
12-1 Month Momentum % | -6.2 | ||
52-Week Range ($) | 2.07 - 8.36 | ||
Shares Outstanding (Mil) | 21.58 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
F-star Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |